Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:05:28 26/06/2024 pm IST			Pre-market 12:15:28 pm
114.8 ^EUR	-0.95%		115	+0.22%

26/06	IPSEN : UBS remains positive ahead of quarterly results	CF
12/06	Ipsen: share price soars, UBS confirms its recommendation	CF

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

June 18, 2024 at 09:30 pm IST

Aggregated presentation by day and by market

Purchases of own shares from June 10th to 14th 2024

Name of the Issuer	Identity code of the Issuer	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	10/06/2024	FR0010259150	5 000	122,0351	XPAR
IPSEN	549300M6SGDPB4Z94P11	11/06/2024	FR0010259150	7 000	122,0734	XPAR
IPSEN	549300M6SGDPB4Z94P11	12/06/2024	FR0010259150	1 863	123,2022	XPAR
IPSEN	549300M6SGDPB4Z94P11	13/06/2024	FR0010259150	6 355	123,9046	XPAR
IPSEN	549300M6SGDPB4Z94P11	13/06/2024	FR0010259150	3 442	123,5264	CEUX
IPSEN	549300M6SGDPB4Z94P11	13/06/2024	FR0010259150	203	123,3000	TQEX
IPSEN	549300M6SGDPB4Z94P11	14/06/2024	FR0010259150	6 000	120,9126	XPAR
IPSEN	549300M6SGDPB4Z94P11	14/06/2024	FR0010259150	2 000	120,7543	CEUX
			TOTAL	31 863	122,3620

Attachment

EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 24_2024

Latest news about Ipsen

IPSEN : UBS remains positive ahead of quarterly results	26/06	CF
Ipsen: share price soars, UBS confirms its recommendation	12/06	CF
IPSEN : UBS remains Buy after FDA approval	12/06	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	11/06	CI
Ipsen: FDA grants approval for treatment	11/06	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	11/06	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	11/06	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	11/06	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	11/06	RE
US FDA approves Genfit and Ipsen's liver disease drug	11/06	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	07/06	MT
Ipsen: research partnership with Marengo extended	07/06	CF
Ipsen Hires New Chief Corporate Affairs Officer	06/06	MT
Ipsen: new Chief Corporate Affairs Officer	06/06	CF
Ipsen: new positive data in PBC	05/06	CF
Ipsen: mandate to an ISP for share buybacks	03/06	CF
Ipsen: new employee shareholding operation	31/05	CF
Ipsen S.A. Approves Dividend, Payable on 3 June 2024	28/05	CI
Ipsen: share price up, analyst raises target	14/05	CF
IPSEN : Barclays raises its target price	14/05	CF
Ipsen Announces Executive Changes	02/05	CI
Ipsen: new President for North America	02/05	CF
IPSEN : Better-than-expected Q1; guidance unchanged	24/04
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	24/04
Ipsen: sales up 11% in Q1	24/04	CF

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 08:20 pm IST

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

114.8 EUR

Average target price

127.3 EUR

Spread / Average Target

+10.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+6.39%	10.13B
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+44.25%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+18.45%	246B
ROCHE HOLDING AG	+2.09%	225B
NOVARTIS AG	+13.03%	218B
AMGEN INC.	+8.61%	168B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals